Continuous glucose monitoring in an infant with panhypopituitarism having hypoglycemia on growth hormone therapy

Kaho Kiuchi, Takeshi Sato, Satsuki Nakano, Tomohiro Ishii, Tomonobu Hasegawa

Research output: Contribution to journalArticlepeer-review

Abstract

The usefulness of continuous glucose monitoring (CGM) in infants with panhypopituitarism (PH) having hypoglycemia is yet to be explored. The potential adverse effects of growth hormone (GH) replacement therapy, such as hyperglycemia, cannot be comprehensively evaluated using the conventional measurement. A 2-month-old infant with PH, including severe GH deficiency, had hypoglycemia despite frequent feeding. Glucose levels were monitored using CGM before and after GH replacement therapy. The proportion of time for hypoglycemia decreased from 4.9 to 0% (p<0.017). Hyperglycemia did not increase. The CGM method did not contribute to any adverse events requiring intervention. Our patient only experienced minor bleeding and no episode of cellulitis. CGM is useful in controlling glucose levels in infants with hypoglycemia and PH.

Original languageEnglish
JournalJournal of Pediatric Endocrinology and Metabolism
DOIs
Publication statusAccepted/In press - 2022

Keywords

  • continuous glucose monitoring
  • growth hormone
  • panhypopituitarism

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Continuous glucose monitoring in an infant with panhypopituitarism having hypoglycemia on growth hormone therapy'. Together they form a unique fingerprint.

Cite this